Galderma has raised its full-year 2026 guidance following a strong first-half performance, with RBC Capital Markets upgrading the company's outlook and citing robust execution across its integrated aesthetics and pharmaceutical portfolio. The upgrade reflects sustained demand for Restylane fillers, Sculptra biostimulator, and Dysport toxin, alongside successful launches in emerging markets including India.